Mr. Hugh MacNaught reports

VENTRIPOINT AND LISHMAN GLOBAL SIGN NON-BINDING TERM SHEET DEFINING LICENSE FOR VMS+ TECHNOLOGY

Ventripoint Diagnostics Ltd. has signed a non-binding term sheet with Lishman Global Inc. outlining the exclusive, non-transferable licence of Ventripoint technology for use within Lishman's echocardiography image platform in the People's Republic of China including the special administrative regions of Hong Kong and Macao.

Previously, Lishman's Chinese subsidiary had received China Food and Drug Administration approval and a certificate of production from the CFDA in the People's Republic of China for the VMS+ product used for analysis of the right ventricle only of the heart. The subsidiary has a good manufacturing practice certified manufacturing facility in China that is able to produce at a scale capable of addressing the Chinese market.

Upon execution, the new licence will enable Lishman and its subsidiaries to fully integrate VMS+ 4.0 within its cart-based and hybrid echocardiography platforms and to market the technology within the territory. The final licence will specify annual minimum volumes once CFDA approval has been secured. Lishman has placed a purchase order for VMS+ components needed to support the manufacture of systems sufficient to support validation of the product and submission to CFDA. Lishman has committed to an investment into Ventripoint.

"We appreciate the ongoing commitment of our Chinese partners to VMS+," stated Hugh MacNaught, president and chief executive officer. "Heart disease remains the No. 1 health care issue in China with nearly twice the rate of hospital admissions for cardiovascular conditions than in North America. China has a higher rate of use of echocardiograms than in North America and is expected to benefit from both the performance improvements inherent to VMS+ that enable greater accuracy of echo studies and the ability of the system to work with sparse data that should reduce the number of repeat studies. Upon CFDA approval, all 32,000 hospitals in China and its territories will gain awareness of a 2-D echocardiography system that generates volumetric results with similar levels of accuracy to cMRI."

"We are looking forward to working closely with Ventripoint to integrate VMS+ within our platforms, secure CFDA approval and actively market our solution to the Chinese clinical community," stated Paul Gibson, chief technology officer of Lishman.

Premarketing efforts are under way in the Chinese market with the objective of establishing a presence within each of the 22 provinces plus the special administrative regions within the country. There are over 2,500 Tier 1 hospitals and a total of 32,000 hospitals, with over 1,000 new hospitals currently under construction.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to an MRI. This affordable, gold standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.